कंपनी का अवलोकन
Functional Brands Inc. (MEHA) operates within the Consumer Defensive sector, specifically focusing on the Packaged Foods industry, where it manufactures and distributes nutraceutical supplements across the United States. The company's product portfolio spans diverse health categories including pain relief, energy enhancement, prenatal care, general wellness, bone and joint support, gastrointestinal health, immunity, cardiac health, detoxification, brain and memory function, sleep aid, and urinary health for pharmaceutical markets. As of the latest available data, the company possesses a market capitalization of $4.07M and reports a trailing twelve-month revenue of $6.61M. The specific employee count is not disclosed in the current financial records. These valuation metrics, particularly the modest market cap relative to annual revenue, indicate that the firm operates as a micro-cap entity with limited scale compared to larger peers in the consumer staples sector. The disparity between its revenue generation and its small market capitalization suggests a specific market positioning or potential liquidity constraints inherent to smaller packaged food distributors.
वित्तीय स्वास्थ्य
The company reported a revenue of $6.61M and a net income of $679,605 over the trailing twelve months, while its EBITDA stands at a negative $1,331,744. The significant divergence between the positive net income of $679,605 and the negative EBITDA of $-1,331,744 reveals a cost structure where non-operating expenses or interest costs heavily weigh against operating earnings before tax and interest. Despite the negative EBITDA, the firm maintains a free cash flow of $562,827, which indicates a degree of financial flexibility derived from capital efficiency or non-cash accounting adjustments rather than core operating profitability. The gross margin is recorded at 52.7%, suggesting the company retains a substantial portion of sales revenue after direct production costs. However, the operating margin is severely depressed at -75.8%, pointing to high overheads or structural inefficiencies in the operating model. The profit margin stands at 11.5%, which is positive but must be viewed in the context of the negative operating leverage. Regarding liquidity, the company holds $2.73M in cash against $2.66M in debt, resulting in a debt-to-equity ratio of 172.85, which signifies a highly leveraged balance sheet rather than a conservative one. The current ratio is 0.90, indicating that current assets are insufficient to cover current liabilities without relying on external financing or asset liquidation. Return on Equity is an exceptional 106.6%, while Return on Assets is negative at -10.7%, a combination that suggests management is utilizing equity to generate returns while the overall asset base generates a loss, likely due to the high debt load relative to assets.
मूल्यांकन आकलन
The trailing P/E ratio is 17.03, whereas the forward P/E is not available, implying that analysts cannot project earnings growth or contraction based on current consensus models. The price-to-book ratio is 2.08, indicating that the market values the company at more than double its tangible book value, which can suggest a premium for intangible assets or a discount if the book value is overstated. The price-to-sales ratio is 0.62, and the EV/EBITDA stands at -2.61, which suggests that traditional valuation multiples are distorted by the negative EBITDA and the company's small market size. The stock has traded between a 52-week high of $8.00 and a 52-week low of $0.13. Given the wide range, the current price sits significantly closer to the low end of the trading band, reflecting recent market volatility or sentiment shifts. The beta value is not available, preventing a direct assessment of the stock's price volatility relative to the broader market index. These alternative metrics, particularly the negative EV/EBITDA, highlight the challenges in valuing a company with negative operating cash flows using standard comparative methods.
Growth & Income
The company experienced a revenue growth of -11.0% year-over-year, while the earnings growth is not available due to the specific financial constraints of the reporting period. The contraction in revenue indicates a decline in sales volume or pricing power within the nutraceutical distribution channel. Since earnings growth data is unavailable, a direct comparison of earnings versus revenue growth rates cannot be definitively calculated, though the negative revenue growth typically pressures earnings stability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the firm reinvests its entire net income of $679,605 back into operations or debt servicing rather than distributing cash to shareholders. This non-dividend profile is typical for micro-cap companies with high debt levels and negative operating margins, prioritizing capital retention over income distribution. The overall growth and income profile reflects a stagnant or declining operational phase where capital preservation is more critical than expansion or shareholder yield.